ferrous gluconate has been researched along with natriuretic peptide, brain in 1 studies
| Studies (ferrous gluconate) | Trials (ferrous gluconate) | Recent Studies (post-2010) (ferrous gluconate) | Studies (natriuretic peptide, brain) | Trials (natriuretic peptide, brain) | Recent Studies (post-2010) (natriuretic peptide, brain) |
|---|---|---|---|---|---|
| 92 | 31 | 25 | 16,317 | 1,867 | 8,887 |
| Protein | Taxonomy | ferrous gluconate (IC50) | natriuretic peptide, brain (IC50) |
|---|---|---|---|
| Atrial natriuretic peptide receptor 1 | Homo sapiens (human) | 0.006 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calabrò, A; Campagna, MS; Franci, B; Nuti, R; Palazzuoli, A; Quatrini, I; Silverberg, DS; Spinelli, T | 1 |
1 trial(s) available for ferrous gluconate and natriuretic peptide, brain
| Article | Year |
|---|---|
Beta-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia.
Topics: Anemia; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Erythropoietin; Ferrous Compounds; Heart Failure; Hematinics; Hospitalization; Humans; Injections, Subcutaneous; Natriuretic Peptide, Brain; Pulmonary Artery; Recombinant Proteins; Ventricular Dysfunction, Left; Ventricular Dysfunction, Right; Ventricular Remodeling | 2009 |